Glycine in dogs: the evidence
What the aging-research databases and the canine literature hold for Glycine (names searched: Glycine). Compiled from DrugAge, the canine aging corpus and FDA CVM FOI summaries; nothing here is inferred.
Lifespan experiments in other species (DrugAge)
8 experiments recorded, by species: Caenorhabditis elegans 6, Mus musculus 2.
NIA Interventions Testing Program rows
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Mus musculus | UM-HET3 | 80000 ppm food | 9 months | until death | Female | 4 | S | 2 | NS | PMID 30916479 |
| Mus musculus | UM-HET3 | 80000 ppm food | 9 months | until death | Male | 6 | S | 5 | S | PMID 30916479 |
Other DrugAge rows (sample)
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | N2 | 10 mM | Unknown | -4 | NS | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 1 mM | Unknown | 10 | S | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 5 mM | Unknown | 3 | NS | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 5 µM | Unknown | 7.85 | S | NA | PMID 30845140 | |||
| Caenorhabditis elegans | N2 | 500 µM | Unknown | 19.54 | S | NA | PMID 30845140 | |||
| Caenorhabditis elegans | N2 | 50 µM | Unknown | 17.6 | S | NA | PMID 30845140 |
Lifespan experiments in dogs (DrugAge)
DrugAge records no dog lifespan experiment for this compound.
Dog-equivalent doses (allometric starting points, not recommendations)
Method: FDA 2005 Km body-surface-area conversion; starting-point heuristic only.
No mg/kg dose in DrugAge to translate (doses reported as ppm of diet or a concentration).
Canine aging literature (Europe PMC corpus)
12 corpus records mention this compound.
Records matching randomized or placebo-controlled trial vocabulary
- Comparison of the precursor, amino acid oxidation, and end-product methods for the evaluation of protein turnover in senior dogs. (PloS one, 2024). PMID 38900837
…The present study compared the methods of precursor (13C-Leucine), end-products (15N-Glycine), and amino acid oxidation (13C-Phenylalanine) to determine the whole…
Top hits in the core tier
- Inhibition of elastin degradation alleviates joint degeneration in aging mice, dogs, and human models. (Proceedings of the National Academy of Sciences of the United States of America, 2026). PMID 42418481
- The role of oxygen free radicals in organ preservation. (Klinische Wochenschrift, 1991). PMID 1798282
- Bilirubin metabolism in canine hepatobiliary and haemolytic disease. (The veterinary quarterly, 1987). PMID 3672859
- Effects of dietary protein on whole-body protein turnover and endocrine function in young-adult and aging dogs. (Journal of animal science, 2001). PMID 11811469
- IDENTIFICATION OF A MULTIDIMENSIONAL FOOD–AMINO ACID–DEFINED CIRCADIAN LONGEVITY ZONE (Innovation in aging, 2017).
- Metabolic phenotype modulation by caloric restriction in a lifelong dog study. (Journal of proteome research, 2013). PMID 23713866
- The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. (Fitoterapia, 2012). PMID 22391022
Trials and cohorts in the canine aging trial registry
No registered study of this compound in dogs.
FDA CVM FOI summaries for dog products
No FDA FOI summary for a dog product contains this ingredient (it is not a marketed veterinary product).
Evidence gaps reported by the dossier tool
- DrugAge has no dog lifespan experiment for this compound.
- No mg/kg animal dose in DrugAge to translate (doses reported as ppm or % of diet).
- No FDA FOI summary for a dog product containing this ingredient.
Reproduce: intervention_dossier(compound="Glycine") in dog-geroscience-mcp.